The Fly

Gossamer Bio downgraded to Underweight from Neutral at JPMorgan

JPMorgan analyst Brian Cheng downgraded Gossamer Bio to Underweight from Neutral without a price target. Following the Phase 2 TORREY readout, the analyst sees path forward for Gossamer to move the seralutinib program forward in a "narrower-than-expected" patient population, and he’s cautious on the company’s outlook in 2023. The Phase 3 plan to include both FC III and FC II with the higher risk criteria is "somewhat of a head-scratcher to us," Cheng tells investors in a research note. The analyst says he’ll need additional data to gain confidence on the next steps.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on GOSS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More